Ovarian Cancer clinical trials in Delaware

5 actively recruiting ovarian cancer trials at 5 sites across Delaware.

Data from ClinicalTrials.gov · last refreshed 2026-11-09

Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology

NCT ID: NCT06580314

Sites in Delaware:

Beebe Medical Center — Lewes, Delaware
Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…

Sponsor: Children's Oncology Group

NCT ID: NCT06513962

Sites in Delaware:

Beebe Medical Center — Lewes, Delaware
Beebe South Coastal Health Campus — Millville, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc

NCT ID: NCT04585750

Sites in Delaware:

Medical Oncology Hematology Consultants — Newark, Delaware

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…

Sponsor: NRG Oncology

NCT ID: NCT04251052

Sites in Delaware:

Beebe Medical Center — Lewes, Delaware
Delaware Clinical and Laboratory Physicians PA — Newark, Delaware
Helen F Graham Cancer Center — Newark, Delaware
Medical Oncology Hematology Consultants PA — Newark, Delaware
Christiana Care Health System-Christiana Hospital — Newark, Delaware

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Delaware:

Massive Bio SYNERGY-AI site — Newark, Delaware

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09